Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAXI for Combined Treatment of Upper Facial Lines
NCT04259086Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Dec 2019
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of daxibotulinumtoxinA in glabellar lines, lateral canthal rhytides, sponsored by Revance Therapeutics. Started Dec 2019; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
glabellar lineslateral canthal rhytides
Beyond the preview
Go deeper on NCT04259086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04259086.